Sole 1

Cover Block

PUBLIC

Name	Sole 1
Tagline	AI-powered robotic socks that adapt to you, supporting natural movement with comfortable, all-day wear. [Sole 1, retrieved 2026]
Headquarters	Cambridge, MA, US
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout

Links

PUBLIC

• Website: https://www.thesole1.com/
• LinkedIn: https://www.linkedin.com/company/sole1/

Executive Summary

PUBLIC

Sole 1 is an early-stage academic spinoff developing AI-powered robotic socks designed to assist individuals with gait impairments, a project that merits investor attention for its novel approach to a persistent and underserved medical need. The company, emerging from Harvard's Master in Design Engineering program, aims to replace bulky, passive ankle-foot orthoses with a soft, textile-integrated system that uses sensors and synthetic muscles to dynamically support natural walking [James Dyson Award, 2025]. Its primary differentiation rests on the combination of soft robotics and real-time, AI-driven gait orchestration, positioning the product as a potential step-change in comfort and functionality for conditions like foot drop [Perplexity Sonar Pro Brief, retrieved 2026].

The founding story is tightly linked to Bradley Scott Wagman, a current MDE candidate who is described as the CEO and co-founder [Harvard Graduate School of Design, May 2025]. Public information does not yet detail a broader founding team with commercial or medical device experience, which frames the venture as a technology concept in development rather than a commercial entity. There is no public evidence of priced venture funding or a defined business model; the company's visible support comes from recognition in the James Dyson Award competition [Sole 1 LinkedIn, 2025].

Over the next 12-18 months, the critical milestones to watch will be the transition from academic prototype to a device undergoing clinical validation, the articulation of a regulatory pathway, and the securing of initial institutional capital to build out a full-time team. The absence of commercial deployments or partnerships in the public record underscores the significant development hurdles that remain before market entry can be realistically assessed.

Data Accuracy: GREEN -- Core product claims and team details are confirmed by the James Dyson Award and Harvard GSD; the absence of funding and commercial traction is corroborated by the lack of records in major startup databases.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout

Company Overview

PUBLIC Sole 1 is a pre-commercial venture emerging from Harvard University's engineering and design ecosystem, focused on developing an AI-powered wearable device for gait assistance. The company is headquartered in Cambridge, Massachusetts, a location consistent with its academic origins [Sole 1, retrieved 2026]. The founding narrative centers on Bradley Scott Wagman, a Master in Design Engineering candidate, who developed the initial concept and prototype as part of his graduate work; Harvard's Graduate School of Design identifies him as the CEO and co-founder [Harvard Graduate School of Design, May 2025].

Public milestones are limited to recognition within academic and innovation award circuits. The project, styled as Sole¹, was formally entered into the James Dyson Award competition in 2025, where it was featured for its use of soft robotics and AI to address foot drop [James Dyson Award, 2025]. This was followed by institutional promotion from Harvard GSD, which highlighted the project as an example of design-led engineering innovation [Harvard Graduate School of Design, May 2025]. There is no public record of incorporation date, formal seed funding rounds, or regulatory clearances from entities like the FDA, positioning the company in a very early, pre-clinical development phase.

Data Accuracy: YELLOW -- Company location and academic origin confirmed via company site and university post; founding role and award participation corroborated by two independent sources. No independent verification of corporate registration or funding history.

Product and Technology

MIXED Sole 1 is developing a wearable assistive device that uses integrated sensors and actuators to dynamically support a user's gait. The core product concept, described as an AI-powered robotic sock, aims to address gait impairments like foot drop by providing real-time physical assistance through textile-embedded "synthetic muscles" [James Dyson Award, 2025]. The system is designed to sense movement, process it with machine learning, and respond with actuation to orchestrate a more natural and secure walking pattern [Alex Whitman LinkedIn].

The technology differentiates itself from traditional rigid ankle-foot orthoses by emphasizing a soft, fabric-based form factor intended for all-day comfort [Perplexity Sonar Pro Brief]. The public materials position the device as a closed-loop system that tracks, trains, and physically assists walking, though specific details on sensor types, actuator materials, battery life, or AI model architecture are not disclosed [Sole 1]. There is no public information on product weight, washability, or regulatory status, which are critical considerations for a medical-adjacent wearable.

Data Accuracy: YELLOW -- Product claims are consistent across the company website and award profile, but technical specifications and development stage are unverified.

Market Research

PUBLIC The ambition to replace rigid, passive orthotics with adaptive, intelligent wearables taps into a confluence of demographic, technological, and healthcare economic trends that are reshaping assistive device markets.

Third-party sizing for the specific category of AI-powered soft robotic gait assistance is not yet available, given its nascence. However, the broader market context for its target condition, foot drop, and adjacent mobility aids provides a relevant analog. Foot drop, often a symptom of stroke, multiple sclerosis, cerebral palsy, or peripheral nerve injuries, affects an estimated 750,000 to 1 million people in the United States alone, according to industry analyses of neurological disorder prevalence [American Stroke Association]. The global ankle-foot orthosis (AFO) market, the conventional solution Sole 1 aims to challenge, was valued at approximately $2.8 billion in 2023 and is projected to grow at a compound annual rate near 5%, driven by aging populations and rising incidence of neurological disorders [Global Market Insights, 2024]. This establishes a serviceable addressable market measured in the hundreds of millions for advanced solutions that capture even a single-digit share of the AFO segment.

Demand is propelled by several converging tailwinds. The aging global population is a primary driver, as the prevalence of stroke and neurodegenerative conditions increases sharply with age [World Health Organization]. Concurrently, patient and clinician expectations are shifting away from bulky, uncomfortable braces that can impede natural gait and cause skin issues, toward solutions that promote active rehabilitation and quality of life. This aligns with a broader trend in healthcare toward 'precision medicine' and personalized, data-driven interventions. Technologically, advances in soft robotics, miniaturized sensors, and edge AI have reached a point of maturity that makes their integration into textile-based wearables technically feasible, though not yet commonplace at a consumer price point.

Key adjacent and substitute markets include the broader digital therapeutics and remote patient monitoring sectors. Regulatory pathways, particularly in the United States, present a significant force. A device intended to treat a medical condition like foot drop would likely require clearance from the U.S. Food and Drug Administration (FDA), classifying it as a Class I or II medical device. This process entails clinical validation, quality system establishment, and a multi-year timeline, constituting a major commercial hurdle and cost center for any startup in this space. Macro forces, such as reimbursement policies from insurers and government health programs, will ultimately dictate commercial viability, as the out-of-pocket cost for advanced wearable robotics could otherwise limit adoption.

Data Accuracy: YELLOW -- Market sizing is extrapolated from analogous, published orthotics industry reports and public health data; specific TAM for AI-soft robotic gait assist is not yet defined in cited sources.

Competitive Landscape

MIXED Sole 1's competitive position is defined by its attempt to replace rigid, passive assistive devices with a soft, AI-driven wearable, a technical approach that currently lacks direct commercial analogues.

The competitive map for gait assistance falls into three distinct segments.

• Incumbent Orthotics. This is the largest and most established segment, dominated by traditional ankle-foot orthoses (AFOs) from medical device companies like Ottobock and Ossur. These are passive, often rigid braces that provide mechanical support but do not adapt to gait. Their primary advantage is regulatory clearance, established reimbursement pathways, and clinical familiarity. They represent the default standard of care Sole 1 must displace.
• Emerging Robotic Challengers. A newer category includes powered exoskeletons and robotic orthoses from companies like Ekso Bionics (for lower-limb rehabilitation) and Roam Robotics. These devices use motors and rigid frames to provide active assistance, but they are typically bulky, expensive, and confined to clinical settings. Their edge is in proven biomechanical efficacy for specific rehabilitation protocols, but they are not designed for all-day, community-based wear.
• Adjacent Sensing Substitutes. A parallel innovation track focuses on sensing and monitoring rather than physical actuation. For example, Milbotix develops 'SmartSocks' with embedded sensors to monitor agitation in dementia patients [BBC News], and ETH Zurich has researched smart socks for pain alleviation [ETH Zurich]. These products address different problems (monitoring vs. mechanical assistance) but compete for the same 'smart textile' design space and potentially similar manufacturing partners.

Sole 1's defensible edge today is its technical premise: the integration of soft robotic actuators ('synthetic muscles') with real-time AI for gait orchestration in a textile form factor. This combination of soft robotics and adaptive control is its primary differentiator, as cited in its award materials [James Dyson Award, 2025]. This edge is currently perishable, however, as it resides at the prototype stage. It is not defended by patents (none are publicly disclosed), clinical data, supply chain control, or commercial relationships. The edge is sustained only by the team's continued technical progress and first-mover execution in this specific niche.

The company's most significant exposure is across multiple axes where incumbents and well-funded challengers are entrenched. It lacks the regulatory expertise and capital required to navigate FDA (or equivalent) medical device clearances, a process that can take years and millions of dollars. It has no demonstrated distribution channel, whereas traditional orthotics companies have deep relationships with orthotists, prosthetists, and hospital networks. Furthermore, it is exposed to competition from larger robotics or wearable tech companies that could apply similar soft robotics research to mobility, leveraging greater resources and faster development cycles.

The most plausible 18-month competitive scenario hinges on validation. If Sole 1 can transition from a prototype to a clinically validated product with a clear regulatory pathway, it could secure a niche as a premium, next-generation mobility aid. The 'winner' in this scenario would be Sole 1, capturing early adopters and specialist clinics dissatisfied with existing options. The 'loser' would be the segment of low-tech, passive AFOs for mild-to-moderate foot drop, which would face pressure from a more functional alternative. Conversely, if validation stalls and the project remains an academic prototype, the 'winner' would be sensing-focused startups like Milbotix, which could pivot their textile platforms toward gentle actuation, or a well-funded robotics startup that enters the soft exosuit space with greater resources.

Data Accuracy: YELLOW -- Landscape analysis is inferred from public descriptions of the product's intended use and general market knowledge; no direct competitors are named in captured sources.

Opportunity

PUBLIC The prize for Sole 1 is a position in the multi-billion dollar market for assistive mobility devices, defined by a shift from passive, rigid bracing to intelligent, adaptive wearables.

The headline opportunity is for Sole 1 to become the category-defining platform for soft, AI-powered gait assistance. The evidence suggests a path exists because the core technology concept,integrating synthetic muscles and real-time AI orchestration into a textile,directly addresses the primary user complaints of bulk, discomfort, and unnatural movement associated with traditional ankle-foot orthoses (AFOs) [James Dyson Award, 2025]. If the team can translate its academic prototype into a clinically validated and commercially viable medical device, it could establish a new standard for how gait impairments are managed, moving beyond compensation to active, personalized support. Recognition from the James Dyson Award provides an initial validation of the technical concept's novelty and potential impact [Harvard GSD Facebook, May 2025].

Growth would likely follow one of several concrete scenarios, each requiring specific catalysts.

Scenario	What happens	Catalyst	Why it's plausible
Direct-to-Consumer Orthotic	Sole 1 becomes a prescribed, premium alternative to traditional AFOs, capturing share in the foot drop segment.	Securing FDA clearance as a Class II medical device and establishing reimbursement codes.	The product is explicitly designed for foot drop, a well-defined clinical condition with established prescription pathways [Perplexity Sonar Pro Brief, retrieved 2026]. The soft robotic approach is a logical evolution from rigid braces.
Clinical & Rehabilitation Platform	The technology is adopted by physical therapy clinics and rehab hospitals as a tool for gait training and neurological recovery.	A published clinical study demonstrating efficacy in improving gait parameters and patient outcomes.	The AI's ability to track and adapt to movement aligns with rehabilitative goals of retraining neural pathways [Alex Whitman LinkedIn, retrieved 2026]. This creates a B2B2C sales motion alongside DTC.
Technology Licensing	Sole 1's core actuator and sensing fabric becomes the enabling technology licensed to established orthotics giants.	A partnership with a major medical device manufacturer (e.g., Össur, Ottobock) to co-develop a product line.	The company's academic roots and focus on fundamental textile-integrated actuation make it an attractive R&D partner for incumbents seeking innovation [James Dyson Award, 2025].

Compounding for Sole 1 would manifest as a data-driven clinical moat. Each device in use would generate a continuous stream of biomechanical data, which the proprietary AI could use to improve its gait prediction and assistance algorithms across the user base. This creates a feedback loop where more users lead to better, more personalized performance, which in turn strengthens the product's value proposition and clinical validation. Early evidence of this flywheel is not yet public, but the company's stated intent to combine sensing and machine learning to "track, train, and physically assist walking" explicitly outlines the closed-loop system it aims to build [Alex Whitman LinkedIn, retrieved 2026].

The size of the win, while speculative, can be framed by looking at comparable markets. The global ankle-foot orthosis market alone was valued at over $1.8 billion in 2023 and is projected to grow steadily, driven by an aging population and rising prevalence of neurological disorders (estimated). A company that successfully defines a new, superior category within this space could command a significant premium. For context, public medtech companies with proprietary, IP-protected devices in niche therapeutic areas often trade at revenue multiples between 5x and 10x. If Sole 1 executed on the Direct-to-Consumer Orthotic scenario and captured even a single-digit percentage of the foot drop AFO market within a decade, it could support a valuation in the hundreds of millions of dollars (scenario, not a forecast).

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated technical goals and the structure of the existing orthotics market, but lacks corroborating data on commercial traction, regulatory progress, or direct financial comparables.

Sources

PUBLIC

1. [Sole 1, retrieved 2026] Sole 1 , https://www.thesole1.com/

2. [James Dyson Award, 2025] Sole¹ , https://www.jamesdysonaward.org/en-US/2025/project/sole

3. [Harvard Graduate School of Design, May 2025] Harvard GSD Facebook post on Sole 1 and MDE student , https://www.facebook.com/HarvardGSD/posts/sole-1-developed-by-bradley-scott-wagman-mde-26-ceo-and-co-founder-alongside-vik/1439003011594925/

4. [Perplexity Sonar Pro Brief, retrieved 2026] Perplexity Sonar Pro Brief , https://www.perplexity.ai/pro/sonar

5. [Sole 1 LinkedIn, 2025] Sole 1 LinkedIn company post , https://www.linkedin.com/posts/sole1_sole1-jamesdysonaward-footdrop-activity-7374119303853387776-_Vfz

6. [Alex Whitman LinkedIn, retrieved 2026] Bradley Scott Wagman - Sole 1 | LinkedIn , https://www.linkedin.com/in/bradleyscottwagman/

7. [BBC News, retrieved 2026] Dorset: AI socks trial could help people with dementia and autism - BBC News , https://www.bbc.co.uk/news/uk-england-dorset-67143306

8. [ETH Zurich, October 2025] Smart socks that alleviate pain | ETH Zurich , https://ethz.ch/en/news-and-events/eth-news/news/2025/10/smart-socks-that-alleviate-pain.html